AnaptysBio (NASDAQ:ANAB) Stock Price Up 3.6%

AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) shares were up 3.6% on Tuesday . The stock traded as high as $22.04 and last traded at $22.03. Approximately 27,661 shares were traded during trading, a decline of 91% from the average daily volume of 309,706 shares. The stock had previously closed at $21.27.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Stifel Nicolaus initiated coverage on AnaptysBio in a research report on Wednesday, February 21st. They issued a "buy" rating and a $50.00 price objective on the stock. JPMorgan Chase & Co. dropped their price objective on AnaptysBio from $30.00 to $28.00 and set a "neutral" rating on the stock in a research report on Monday, April 1st. Piper Sandler started coverage on AnaptysBio in a research report on Friday, February 16th. They issued an "overweight" rating and a $80.00 target price for the company. BTIG Research began coverage on shares of AnaptysBio in a research note on Monday, February 26th. They set a "buy" rating and a $55.00 target price on the stock. Finally, SVB Leerink started coverage on shares of AnaptysBio in a research note on Tuesday. They issued an "outperform" rating and a $47.00 price target for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $46.22.

AnaptysBio Stock Up 0.3 %

The company has a market cap of $571.06 million, a PE ratio of -3.50 and a beta of -0.30. The business's fifty day moving average is $23.47 and its 200-day moving average is $20.52.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its quarterly earnings results on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share for the quarter, topping the consensus estimate of ($1.74) by $0.15. The business had revenue of $9.01 million for the quarter, compared to analysts' expectations of $3.28 million. AnaptysBio had a negative net margin of 953.66% and a negative return on equity of 119.42%. Analysts forecast that AnaptysBio, Inc. will post -6.25 EPS for the current fiscal year.

Insider Activity at AnaptysBio

In related news, insider Eric J. Loumeau sold 5,000 shares of the business's stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.00, for a total transaction of $125,000.00. Following the completion of the transaction, the insider now directly owns 3,240 shares in the company, valued at approximately $81,000. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other AnaptysBio news, CEO Daniel Faga sold 145,940 shares of the stock in a transaction on Friday, March 22nd. The stock was sold at an average price of $22.78, for a total value of $3,324,513.20. Following the completion of the sale, the chief executive officer now owns 752,087 shares in the company, valued at approximately $17,132,541.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Eric J. Loumeau sold 5,000 shares of the firm's stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.00, for a total value of $125,000.00. Following the sale, the insider now directly owns 3,240 shares in the company, valued at $81,000. The disclosure for this sale can be found here. Over the last three months, insiders have sold 157,005 shares of company stock worth $3,586,199. Corporate insiders own 35.50% of the company's stock.

Institutional Trading of AnaptysBio

Several institutional investors have recently made changes to their positions in ANAB. Woodline Partners LP lifted its holdings in AnaptysBio by 125.1% in the 2nd quarter. Woodline Partners LP now owns 1,034,549 shares of the biotechnology company's stock worth $21,043,000 after purchasing an additional 574,987 shares in the last quarter. First Light Asset Management LLC lifted its holdings in shares of AnaptysBio by 56.4% in the fourth quarter. First Light Asset Management LLC now owns 1,237,178 shares of the biotechnology company's stock worth $26,500,000 after buying an additional 446,372 shares in the last quarter. Eventide Asset Management LLC bought a new position in shares of AnaptysBio during the third quarter worth $7,669,000. Millennium Management LLC grew its stake in AnaptysBio by 1,050.7% during the fourth quarter. Millennium Management LLC now owns 322,802 shares of the biotechnology company's stock valued at $10,004,000 after acquiring an additional 294,750 shares in the last quarter. Finally, Palo Alto Investors LP increased its holdings in AnaptysBio by 59.3% in the 4th quarter. Palo Alto Investors LP now owns 686,882 shares of the biotechnology company's stock valued at $14,713,000 after acquiring an additional 255,658 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.